These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10778172)

  • 1. [BCA225].
    Kumamoto K; Kannagi R
    Nihon Rinsho; 1999 Dec; 57 Suppl():495-7. PubMed ID: 10778172
    [No Abstract]   [Full Text] [Related]  

  • 2. [BCA225].
    Kumamoto K; Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():669-71. PubMed ID: 16149607
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BCA225].
    Kannagi R; Fujii M; Kumamoto K
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():709-13. PubMed ID: 20960855
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum levels of CA15-3, KL-6 and BCA225 are positively correlated with each other in the general population.
    Ri G; Ohno S; Yamamoto T; Ito E; Furutani M; Furutani Y; Umeda Y; Tsukahara T; Hagita N; Matsuoka R
    Anticancer Res; 2009 Oct; 29(10):4239-42. PubMed ID: 19846980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological tumor markers for monitoring breast cancer.
    Sölétormos G
    Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tumor markers in breast cancer].
    Harada Y; Ohuchi N; Ishida T; Ohnuki K
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum TAG-72 in women with breast cancer: an example of serum/tissue discrepancy of a tumor marker].
    Ruibal A; Sagredo E; Soriano A; Roiz MC
    Med Clin (Barc); 1989 Jan; 92(1):39. PubMed ID: 2716383
    [No Abstract]   [Full Text] [Related]  

  • 10. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3.
    Cazin JL; Gosselin P; Boniface B; Demaille MC; Demaille A
    Anticancer Res; 1992; 12(3):719-24. PubMed ID: 1622129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytokines as tumor markers in breast cancer].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2003; 57(4):455-63. PubMed ID: 14626202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour markers in breast cancer--EGTM recommendations. European Group on Tumor Markers.
    Anticancer Res; 1999; 19(4A):2803-5. PubMed ID: 10470245
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnostic contribution of serum levels of tumor markers in adenocarcinoma of the breast].
    Cioffi M; Fratta M; De Lucia D; Bresciani F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):33-4. PubMed ID: 2092145
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tumor markers in breast cancer].
    Inaji H; Komoike Y; Motomura K; Koyama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():140-5. PubMed ID: 11025987
    [No Abstract]   [Full Text] [Related]  

  • 15. Old and new markers for breast cancer prognosis: the need for integrated research on quantitative issues.
    Biganzoli E; Boracchi P
    Eur J Cancer; 2004 Aug; 40(12):1803-6. PubMed ID: 15288279
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum degradome markers for the detection of breast cancer.
    van Winden AW; van den Broek I; Gast MC; Engwegen JY; Sparidans RW; van Dulken EJ; Depla AC; Cats A; Schellens JH; Peeters PH; Beijnen JH; van Gils CH
    J Proteome Res; 2010 Aug; 9(8):3781-8. PubMed ID: 20557135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CA72 -4 (TAG72)].
    Mizumoto Y; Kyo S; Takakura M; Nakamura M; Inoue M
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():717-9. PubMed ID: 20963906
    [No Abstract]   [Full Text] [Related]  

  • 18. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression.
    Abd Hamid UM; Royle L; Saldova R; Radcliffe CM; Harvey DJ; Storr SJ; Pardo M; Antrobus R; Chapman CJ; Zitzmann N; Robertson JF; Dwek RA; Rudd PM
    Glycobiology; 2008 Dec; 18(12):1105-18. PubMed ID: 18818422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mucin markers in metastatic breast cancer].
    Bieglmayer C; Breitenecker G; Szepesi T
    Gynakol Rundsch; 1990; 30 Suppl 1():142-4. PubMed ID: 2079249
    [No Abstract]   [Full Text] [Related]  

  • 20. [C-erb B-2 protein in the sera of breast cancer patients].
    Narita T; Funahashi H; Satoh Y; Takagi H
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):909-11. PubMed ID: 1351384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.